European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis by Sachchithanantham, S et al.
1 
 
  
A European collaborative study of natural history, 
outcomes and validation of prognostic/response criteria in 
IgM related AL amyloidosis  
Sajitha Sachchithanantham1, Murielle Roussel1,2,Giovanni Palladini3, Catherine Klersy4, 
Shameem Mahmood1, Christopher Paul Venner5, Simon Gibbs6, Julian Gillmore1, Helen 
Lachmann1, Philip N Hawkins1, Arnaud Jaccard7, Giampaolo Merlini3, and Ashutosh D 
Wechalekar1 
1Centre for Amyloidosis and Acute Phase Proteins, University College London Medical 
School, London, UK 
2 Haematology Department, CHU Purpan, Toulouse, France 
3Amyloidosis Research and Treatment Centre, Fondazione IRCCS Policlinico San Matteo and 
Department of Molecular Medicine, University of Pavia, Pavia, Italy  
4Servizio di Biometria e Statistica, Direzione Scientifica, Pavia, Italy 
5University of Alberta, Cross Cancer Institute, Edmonton, Alberta,  Canada 
6 Haematology Department, Westmead Hospital, Sydney, Australia 
7Centre de Référence des Amyloses Primitives et des Autres Maladies par Dépôts 
d’Immunoglobuline, CHU Limoges, France 
Word count: Abstract – 275, Main text - 30003709 
 
 
Correspondence: 
Dr Ashutosh Wechalekar 
National Amyloidosis Centre 
University College London (Royal Free Campus) 
Rowland Hill Street, London NW32PF 
UK 
Email: a.wechalekar@ucl.ac.uk 
 
Running head: IgM related AL amyloidosis: a European collaborative study 
Fundings: Nil 
Disclosers: Nil 
2 
 
 
Abstract: 
Purpose 
IgM related AL amyloidosis, accounting for 6-10% of all AL cases, is a rare and poorly studied 
clinical entity.  Its natural history and management is not clearly defined.  Prognostic and 
response criteria for AL in general have not been validated in this population.   
Patients and Methods 
We retrospectively gathered 250 patients diagnosed with IgM-AL amyloidosis from three 
European amyloidosis centres. Clinical features, haematological response and overall survival 
were analysed. The validity of current staging and response criteria in non-IgM AL were 
applied to this series to assess their utility in this patient cohort.  
Results 
Patients with IgM-AL have a significant IgM paraprotein (median 10g/L), lambda light chain 
isotype is less frequent and dFLC is evaluable (>50 mg/L) in only 2/3 cases. Bone marrow 
showed clear Non-Hodgkin’s lymphoma as the underlying disorder in 54%.  Cardiac 
involvement is less common (45%) with more frequent lymph node (20%) and neuropathic 
involvement (28%) compared to non-IgM AL. 57% of patients achieved a haematological 
response (14% VGPR/CR) with median OS not-reached for patients achieving VGPR/CR, 64 
months for PR and 28 months for non-responders (p<0.001). On multivariate analysis, cardiac 
involvement/advanced Mayo disease stage, PN involvement, and low albumin <30g/L were 
independent factors impacting survival. Combining abnormal NT-proBNP and troponin-T with 
low albumin and presence of PN gives a better risk model: median OS of patients with none, 
one or two/more abnormal factors were 73, 55 and 17 months respectively.  
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Conclusion 
IgM-AL is a distinct clinical entity. Low risk disease can be defined by combining cardiac with 
novel prognostic markers.  Deeper haematological responses translate into improved outcomes; 
yet deep responses remain dismally poor showing the urgent need for novel therapies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction: 
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Amyloidosis is a rare systemic disorder of protein misfolding and results from extracellular 
deposition of beta pleated aggregates of fibrillar proteinaceous materials.  The most common 
type of amyloidosis is light chain amyloidosis (AL), where the amyloidogenic precursor protein 
is a monoclonal immunoglobulin light chain.1    In about 45-55% of cases, an intact monoclonal 
immunoglobulin protein can be identified which is usually IgG or IgA paraprotein associated 
with an underlying plasma cell disorder.  In 5-7% of patients, AL amyloidosis is associated 
with an underlying IgM paraprotein, described in small series by our groups and from the 
US.3,4,5  It has previously been suggested that IgM-AL amyloidosis should be classed as a 
distinct clinical entity with several distinguishing clinical features from non-IgM AL 
amyloidosis.6,7  Given its rarity, IgM-AL remains poorly studied.  Since this disorder is 
different, as all patients have an intact monoclonal protein and appear to have an underlying 
lymphoproliferative disorder, criteria validated for non-IgM AL have not been formally tested 
in this disease.  The treatment paradigms designed for non-IgM AL have been used in IgM-AL 
amyloidosis, which may not always be appropriate.   
We report the utility of prognostic and response criteria, validated in non-IgM AL amyloidosis 
in a large series of 250 patients with IgM associated AL amyloidosis seen at three major 
European amyloidosis centres.  We also report the clinical characteristics, and outcomes in this 
patient cohort.  The current report is, to our knowledge, the largest series of IgM related 
amyloidosis.  
Patients and methods: 
Two hundred and sixty one newly diagnosed patients with IgM related AL amyloidosis from 
amyloidosis centres in London (United Kingdom, 149 patients), Pavia (Italy, 81 patients) and 
Limoges, (France, 31 patients) between January 1990 and December 2012 were, 
retrospectively, included in this study. IgM related AL amyloidosis was defined as all patients 
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with confirmed AL amyloidosis with detectable IgM paraprotein demonstrated in the serum or 
urine by electrophoresis and immunofixation, in the absence of any other monoclonal protein.  
The presence of amyloid was confirmed by characteristic Congo red staining  and AL-type  
was confirmed by either immunohistochemistry immuno-electron microscopy or 
immunofluorescence and exclusion of hereditary amyloidosis by appropriate gene sequencing.   
All patients were treated according to local protocols and had rigorous protocolized 
assessments which included evaluation of clonal disease at baseline and after each line of 
therapy and organ function at baseline.  The study was performed with institutional review 
board approval, and informed consent was obtained from each patient in accordance with the 
Declaration of Helsinki. 
Outcome measures: 
Organ involvement was assessed according to the Consensus Opinion from the 10th 
International Symposium on Amyloid and Amyloidosis.8  Outcome measures comprised of 
overall patient survival (OS),hematologic response (HR) to first line treatment and organ 
response. The primary outcome measure was OS.  The validity of currently published staging 
and response criteria in non-IgM AL were applied to this series to assess the utility of those 
criteria in this patient cohort including impact of HR to treatment on survival.  HR was assessed 
by serum and urine electrophoresis, immunofixation and free light chain (FLC) assay.  HR 
were defined as per the amyloidosis consensus guidelines.8   FLC values were considered 
evaluable for assessing response if the pre-treatment difference between the involved and 
uninvolved free light chain (dFLC) was >50 mg/L with an abnormal FLC ratio.  HR were 
assessed as per the consensus criteria published by Palladini et al 9 and by use of serum 
paraprotein (PP) response.  The response was assessed as the best achieved response after 
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starting chemotherapy and before any further therapy was given. Those who died early prior to 
response assessment were categorized as non-responders in the intent to treat analysis (ITT). 
Survival was described by means of  its median  and displayed graphically by Kaplan Meier 
curves. The association of a series of candidate predictors and survival was assessed by 
Cox models. The proportional hazard assumption was tested and satisfied in all cases. Linearity 
of ordinal predictors was verified by means of the likelihood ratio test to compare nested 
models. Response was treated as a time dependent variable. The effect modification on the 
relationship of response and survival by Mayo Stage was assessed by including an interaction 
term in the model. All non-co-linear variables with p-value<0.1 at univariable analysis and 
with missing data below 20% were included in a multivariable Cox (time-dependent) 
regression model. For all Cox models, clustered robust standard errors were computed to 
account for within-country correlation. Model validation was performed by calculating the 
shrinkage coefficient/noise for calibration and the Harrell's c statistic for discrimination.A 2-
sided p-value<0.05 was considered statistically significant. Stata 13.1 (StataCorp, College 
Station, TX, USA) was used for computation. 
Results: 
Two hundred and sixty one patients with isolated IgM paraprotein related AL amyloidosis were 
identified from three European centres.  Eleven patients had localised amyloidosis and were 
excluded from analysis.  Ninety five percent (250) of patients had systemic AL amyloidosis 
and were included in this retrospective study.  The baseline demographics including cardiac 
disease stage are given on Table 1.  45% of those referred before 2004 were >67 years of age, 
this increased in 2004-2009 period to 51% and then to 64% in 2010-2012.Cardiac, renal, soft 
tissue and liver involvement were in 45%, 68%, 35% and 17 % of patients at diagnosis.  Mayo 
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stage (available in 216 (86%)) 1, 2 and 3 disease was seen in 40%, 34% and 26% of patients 
respectively.  . Lymph node involvement was detected in 20% of patients at presentation. 
A total of 131 (52%) of the patients had a clearly identified lymphoproliferative disorder 
(predated the AL diagnosis in 39). Thirty four (14%) had a normal bone marrow (BM) with no 
detectable clonal dyscrasia.  Fifteen (6%) had plasma cell predominance in the BM.  The BM 
details were not available for 70 patients (28%).  Of the patients with an underlying 
lymphoproliferative disorder, 97 (39%) had lymphoplasmacytic lymphoma, 34 (14%) had a 
Non-Hodgkin’s lymphoma (NHL) not specifically classified.  2 had chronic lymphocytic 
lymphoma and 2 had Follicular Lymphoma.   
Treatment and response: 
Two hundred and twenty eight (91%) patients were treated and eight died prior to starting 
chemotherapy.  Fourteen patients were excluded from treatment analysis as treatment 
information was not available.  Twenty two different combination of regimen were used as first 
line;  grouped into ten categories for ease of analysis and are shown on table 2.  The median 
number of lines of therapies was 1 (range 1-5).  Figure 1 shows the changing trend in treatment 
profile since 1990.  The use of Melphalan, Chlorambucil and conventional chemotherapy has 
reduced over time.  Purine Analogues, traditional chemotherapy regimens and Thalidomide 
were predominantly used during 2005-2009.    Since 2010, the use of Rituximab in combination 
with bortezomib or combination chemotherapy (R-CD or R-CVP/CHOP) was most frequent.  
212 of the treated patients had evaluable paraprotein (81 by paraprotein alone) or dFLC (12 by 
dFLC alone) and 119 by both. HR data was available for 172 patients (78%) (M-protien data 
in 49 patients). On an ITT analysis, 102 (57%) patents achieved HR (43% partial response 
(PR), 9% very good partial response (VGPR) and 5% complete response (CR)). Of the 49 
patients evaluable for M-protein only response (dFLC not evaluable), 24 achieved PR, 1 CR 
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and 24 were non-responders.   Of the patients with both evaluable M-Protein and dFLC, nine 
patients had no dFLC response but had achieved PR based on M-protein response.  For all other 
patients, dFLC responses were same as or of a deeper grade than corresponding M-protein 
response. Fifteen patients deemed as non-responders by M-protein alone, had achieved PR 
(13) and VGPR (2) by dFLC response.  Table 2 details treatment regimes, HR with proportion 
achieving VGPR/CR, median OS and 2 year survival rates and time to next treatment for 
patients treated with the various first line therapies.  The numbers are too small in individual 
group for meaningful statistical comparisons.  
Survival analysis: 
The median overall survival was 47.9 months (figure 2a). There was no improvement in 
survival over time as shown in figure 2b:  Patients with no identifiable clonal infiltrate in the 
BM had best survival (54 months) compared to a lymphoid infiltrate or a plasma cell 
predominant infiltrate (44 months and 23 months respectively).     
Figure 2c-f show survival by disease characteristics. Presence of cardiac involvement conferred 
significantly worse outcomes (median OS 21 vs. 62.5 months for no cardiac involvement), as 
did worse  Mayo disease stage(median 73, 24 and 10 months for stage 1, 2 and 3 respectively).  
Other factors associated with poorer outcomes included peripheral neuropathy (PN) or 
autonomic neuropathy (AN) , low serum albumin (<30g/L) (29 vs 50 months, p=0.008) or 
higher dFLC (>180 mg/L) (18.9 vs 48 months, p=0.021).  In this study only 13% of patients 
with neuropathy received bortezomib or thalidomide.  . Table 3 details univariate and 
multivariate analysis of factors affecting overall survival (.different multivariate models of NT-
proBNP and Mayo stages in supplementary table 2).  Combining factors independently 
predictive of survival (NT-proBNP, troponin T, albumin and presence of PN), a new risk model 
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is outlined in figure 3a with median survival of patients with none, one or two/more abnormal 
being 73, 55 and 17 months respectively.  
Patients who responded to first line treatment (69 months) had a significantly better survival 
compared to the non-responders (28 months) (p<0.012) (figure 3b).  Very good partial response 
as defined by dFLC remained a predictor of outcome with patients achieving a VGPR/CR with 
median OS not reached vs. 64 months for those with a PR, (p=0.183) and 22 months for non-
responders <0.0001 (figure 3c).  Patients with only by M-protein response, median OS was not 
reached for responders.. Responders within mayo stage 2 and 3 had a significantly better 
outcome compared to the non-responders, whereas, there was no significant difference within 
mayo stage 1 group, however, the median OS for the responders was 134 months and only 62 
months for the non-responders within this latter group (figure 3d-f).  Median time to next 
treatment (TTNT) was 12 months with no significant difference by organ involved (isolated 
cardiac, renal and liver involvement with 7, 9 and 9 months respectively).  
Organ response: 
On an ITT analysis of organ response, cardiac, liver and renal responses were 3/57 (5%), 7/26 
(27%) and 19/108 (18%). Organ response rates are much lower in the IgM cohort compared to 
that seen in the IgA/IgG-AL cohort in the era of novel agents. 11 
Discussion 
Systemic AL amyloidosis associated with IgM-paraprotein is relatively uncommon variant of 
AL amyloidosis, accounting for 6% of AL patients.3  Our groups have previously reported 
small series of IgM-AL suggesting that this sub-group needs to be clearly recognised as a 
distinct condition and considered for specific treatment targeting the underlying clone.5,7,12,13  
The cohort reported here is the largest series of patients with IgM related AL amyloidosis from 
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three major European centres and reports the presenting features, response to treatment and 
clinical outcomes.  This large series allowed identification of novel prognostic factors 
(peripheral neuropathy and low serum albumin) unique to this patient population.  We confirm 
that deeper haematological responses, although still rare, translate into a significant survival 
advantage.  
Since AL amyloidosis is driven by the amyloidogenic light chains, the overall pattern of organ 
involvement remains broadly similar to that seen in non-IgM AL amyloidosis.14,15  The striking 
difference is less common cardiac involvement compared to non-IgM AL amyloidosis (45% 
vs ~70% respectively)15  which may be due to the relatively lower proportion of lambda light 
chain isotype in IgM  and lower light chain clonal burden.  There is a higher incidence of soft 
tissue and lymph node (35%) involvement, (similar to previous reports4,5) possibly due to co-
existent lymphoma clone at the respective site.  The prognostic impact of nerve involvement 
was unexpected.  Only 13% of patients with nerve involvement received bortezomib (or 
thalidomide) base regimes, raising question about lack of exposure to novel therapies driving 
poorer prognosis.   
Clear and accurate identification of the underlying clonal disorder is key to accurate treatment 
selection.  The underlying clonal disorder is distinctly a non-Hodgkins lymphoma in 54% (of 
those who had bone marrow biopsy available) of the cases in this series but plasma cell 
infiltration is still reported in a proportion (6%) as indeed is the lack of identifiable clonal 
infiltrate (14%).  The latter group possibly indicates that  the clone  was mainly in lymph nodes 
with no BM involvement, justifying  a lymph node biopsy.  Given the substantial variability in 
BM reporting as evident above, accurate haematopathology review and use of molecular 
markers like MYD88 is critical.  The poorer outcome in the group with excess plasma cells, 
perhaps, lends credence use of agents which actively target plasma cells, such as proteasome 
inhibitors, to be preferentially used in these cases. Cross sectional  imaging in IgM AL 
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amyloidosis, particularly to assess lymph node, soft tissue and lung disease, may have an 
important role.  Particularly, in those with lymph node involvement where lymphoid 
component will respond to treatment but the amyloid may not change – posing a challenge in 
assessing “true” extent of response.  Imaging is important in this condition and its role, 
including PET-CT, needs clarification.  
Contrary to clinical impression and previous publications, 74% of patients in this series had 
abnormal FLC.   Patients with either FLC or paraprotein only response had improved outcomes.  
Since all patients had a detectable M-protein at a reasonable level, contrary to emerging 
literature in non-IgM AL amyloidosis, we feel that in IgM-AL both light chains and paraprotein 
should be used for response assessment.   
Based on smaller series from us and other groups, treatment of patients with IgM-AL has 
evolved; patients with IgM AL do not fare well with the “standard” plasma cell directed 
treatments, not an unsurprising observation as most cases have an underlying NHL.  This series 
encompasses the changing treatment profiles in this condition.  Although a variety of regimes 
were used, Rituximab now forms a backbone in most regimes and is used with conventional 
alkylators (R-CD), purine analogues, bendamustine or with bortezomib with possible resultant 
better outcomes.  However, the striking paucity of VGPR/CR (14% vs 44% in bortezomib 
treated non-IgM patients (56% in mayo stage I cases))16, highlights the difficulties of deep 
clonal eradication in low grade NHL.  There is a suggestion in this series that patients who 
reach VGPR have much better outcomes than lesser degrees of responses – 75% alive at 5 
years compared to just over 50% of those with PR.  This series validates that the goal of 
VGPR/CR still remains the therapeutic end point in patients with IgM-AL even in Mayo 
cardiac stage 2 or 3 disease.  Achieving improvement in organ function is the final goal of 
therapy.  However, tThe lack of deep clonal responses also translated into poorer organ 
responses in this patient cohort compared to non-IgM AL.17,18 
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Although the median OS in this series is similar to previous reports19, OS of early stage disease 
(Mayo stage 1 and 2) in IgM is poorer than non-IgM patients (75% OS at 5 years for stage I 
vs. >90% in non-IgM AL20-22); half the expected OS in Mayo stage 2 patients compared to non-
IgM setting (2 vs ~4 years respectively).  Paradoxically, OS of stage 3 appears no different 
compared to non-IgM-AL possibly due to a lower incidence of very advanced cardiac AL (NT-
proBNP >8500 ng/L)  in this series  and secondly, the lack of a deep clonal response allowing 
for disease progression.  This re-emphasises the need for development of novel agent based, 
highly and rapidly effective regimes for this patient group.   
The factors impacting overall survival are dominated by cardiac involvement as in other non-
IgM cases.  Other poor prognostic factors were: older age (>67 yrs.) at presentation, AN or PN 
involvement, serum albumin <30g/L, dFLC >180mg/l, paraprotein >10g/L, liver involvement 
and >2 organs involvement.  On multivariate analysis, independent factors impacting survival 
were presence of cardiac involvement (or mayo stage), PN and low serum albumin.  The latter 
two are novel prognostic markers in this patient group.  Serum albumin levels of <30g/L, has 
been previously reported to be associated with worse outcomes in IgM-AL and the utility of 
this marker is confirmed in current study.5,7  The finding of PN as a significant factor has 
important therapeutic implication as proteasome inhibitor, bortezomib appears to be effective 
and PN may potentially limit its use. We propose new prognostic staging system for IgM-AL 
amyloidosis that include presence of  PN and low serum albumin in figure 3a (supplementary 
table 1).  A further study including patients from other major centres to validate this finding is 
in progress. 
We acknowledge that this study has several limitations including its retrospective nature, small 
number of patients in each treatment group, lack of detailed haematopathology and imaging 
for lymphoma diagnosis.  Prospective studies are t challenging due to rarity of IgM-AL and 
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difficulty of undertaking studies across national boundaries – wider international collaborative 
efforts may help to clarify these questions.    
In summary, IgM related AL amyloidosis is a rare but distinct clinical entity of AL amyloidosis.  
A higher proportion of patients have lymph node involvement and lower proportion have 
cardiac involvement.  Accurate characterisation of underlying clonal disorder is critical in the 
diagnostic work up of patients with IgM-AL.  A revised staging system is proposed in this 
disease which requires further validation.  Striving for VGPR/CR continues to be the goal of 
therapy.Currently, ASCT and bortezomib based regimes appear to be associated with best 
responses although the prolonged time to next treatment seen with FCR raises the important 
issue of accurately targeting the lymphoid component of the clone for longer term disease 
control.  Novel targeted therapies need to be further explored in this condition. International 
tissue and data registry would help to broaden the understanding of this disease.     
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Figure Legends 
 
Figure 1: Shows the change in treatment trend over time for the ten different treatment groups; 
ASCT – Autologous Stem Cell Transplantation, Bortezomib based regimens, Chlorambucil, 
Conventional chemotherapy - CHOP/COP/VAD, PA – Purine Analogues, Melphalan, 
Rituximab + Conventional chemotherapy, RPA – Rituximab + Purine Analogues, 
RBortezomib – Rituximab + Bortezomib and Thalidomide based regimens, for the time period 
– pre 2004, 2005-2009 and after 2010.   
Figure 2: Shows survival curves: a) Overall survival of patients with IgM related AL 
amyloidosis with median survival of 47.9 months; b) Survival over time - there was no 
improvement in the survival over the study period. Median OS - 48 months before 2004, 50 
months for 2005-2009 and not reached for 2010 -2012; Figures c-f show survival by organ 
involvement: c) Survival curves by mayo stage - median OS for stage 1, 73 months,  stage 2, 
24 months and stage 3, 10 months (log rank p <0.001); d) Autonomic nervous system  (ANS) 
involvement vs no involvement, median OS 15 months and 51 months respectively (p<0.001); 
e) albumin <30g/l vs >30g/l, median OS 29 months and 50 months respectively (p=0.008); f) 
dFLC >180mg/L vs dFLC <180mg/L, median OS 19 months and 48 months respectively 
(p=0.021).  
Figure 3a-f: a) Shows the proposed new staging system using - BNP >332ng/L, cTnT >0.035 
µg/L or cTnI >0.1µg/L, Albumin <30g/L and Involvement of PNS. Stage 1 – no abnormal 
features, Stage 2 – one abnormal feature and Stage 3 – two or more abnormal features. The 
median OS for stage 1, 2 and 3 were 73, 55 and 17 months respectively; b-f) Survival by 
response for entire cohort, by mayo stage and type of response; b) Median OS for those 
responded to first line treatment - 69 months and for non-responders – 28 months (p<0.012); 
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c) Median OS for those achieving a VGPR or better was not reached, PR was 64 months and 
for non-responders was 22 months;  d) Median OS for responders within mayo stage 1 was 134 
months and for non-responders was 62 months  (p=0.129);  e) median OS for responders within 
mayo stage 2 was 54 months and for non-responders was 8 months, (p<0.001) and f) Median 
OS for responders within mayo stage 3 was 29 months and for non-responders was 8 months, 
(p=0.005).   
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Table 1- Patient demographics at presentation 
 
 Median No of patients (%) 
Age at presentation (0%) 67 (38-89) 250 
Sex (Male: Female ratio) (0%) 1.7:1  
Paraprotein concentration (g/L)  
(14%) 
10 (IF-70)  
Monoclonal  light chain type (0%)   
 Kappa  100 (40) 
 Lambda  150 (60) 
Abnormal FLC ratio (12%)   163 / 221 (74) 
Evaluable FLC (12%)  147 / 221 (67) 
dFLC (mg/l) at presentation 
 Kappa 
 Lambda 
122.3 (30-7762) 
100.5 (30-1343) 
155 (41-7762) 
 
Hemoglobin (g/L) (13%) 12.5 (7.8-17.7  
Total white cell count (x 109/L) 
(30%) 
7.04 (0.56-23)  
Platelets (x 109/L) (30%) 294.5 (18-757)  
Creatinine (µmol/L) (2%) 97.2 (42-ESRD)  
Albumin (g/L) (11%) 35 (12–49)  
Alkaline phosphatase (IU/L) (13%) 129 (42-3488)  
24 hour proteinuria (g/24 hrs) (8%) 1.78 (0-45)  
Creatinine clearance (ml/min) (55%) 64 (ESRD-157)  
Organ involvement (1%)   
No of organs involved 2 (1-6)  
 1  81 (32) 
 2  89 (36) 
 3 or more  80 (32) 
Cardiac (0.8%)  112 (45) 
 NT-proBNP (ng/L) (14%) 
NT-proBNP >8500 ng/L 
 609 (17-120737) 
19 (9%) 
 
 cTnT (ng/ml) / (22%) 
 cTnI (ng/ml) 
0.020(0.003-0.467) 
0.020(0.002-0.599) 
   
 IVS (mm) (20%) 12 (7-22) 232 (79) 
Mayo stage (14%)  216 (86) 
 Stage 1  87 (40) 
 Stage 2  73 (34) 
 Stage 3  56 (26) 
Renal (0%)  169 (68) 
Liver (0%)  41 (17) 
Soft tissue (0%) 
 Lymph node 
 80 (35)  
50 (20) 
PNS (0%)  37 (15) 
ANS (0.4%)  32 (13) 
GI (1%)  22 (9) 
IF – immunofixation; dFLC - difference between involved (amyloidogenic) and uninvolved 
free light chain; ESRD – end stage renal failure; NT-proBNP - N-terminal pro–natriuretic 
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peptide type B; cTnT- Cardiac Troponin T; IVS - interventricular septum; PNS – peripheral 
nervous system; ANS - autonomic nervous system; GI - Gastrointestinal system. 
  
23 
 
 
Table 2 – Haematological response, median OS, two year survival and time to next treatment 
(TTNT) for each treatment group  
Treatment type  N (%) Proportion with 
cardiac 
involvement 
(Mayo stage 3, 
%) 
PR or 
better % 
(VGPR 
or better, 
%) 
Median 
OS 
(Months)  
2 year 
survival 
(%) 
TTNT 
(Months) 
ASCT  4 (1.8)  25 (0) 100 (33) NR 100 NR 
Chlorambucil / 
Cyclophosphamide  
62 
(27.1)  
41 (25) 46 (7) 50.8 73 11 
CHOP/COP/VAD  14 (6.1)  21 (33) 62 (0) 49.8 79 21 
Melphalan +/-Dex   53 (23)  58 (28) 70 (26) 22.9 49 8 
FC/CLAD  12 (5)  42 (25) 40 (0) 31.4 58 10 
FCR   11 (4.8)  27 (0) 70 (30) 69.4 73 63 
RCD/RCHL/RCVP/R
CHOP/RTD   
45 
(19.7) 
44 (23) 63 (15) 91.9 63 20 
Bortezomib   8 (3.5) 50 (25) 57 (42) NR 88 NR 
Rituximab+Bortezomi
b  
8 (3.5) 50 (25) 86 (29) 30.2 75 19 
Thalidomide  11 (4.8) 36 (27) 63 (9) 37.9 55 5 
ASCT – Autologous stem cell transplantation; CHOP - cyclophosphamide, vincristine, 
doxorubicin and prednisolone; COP - cyclophosphamide, vincristine and prednisolone; VAD 
– Vincristine, Adriamycin and dexamethasone; FC – Fludarabine and cyclophosphamide; 
CLAD – Cladribine; FCR – Fludarabine, cyclophosphamide and Rituximab; RCD – 
Rituximab, cyclophosphamide and dexamethasone; RCHL: Rituximab and Chlorambucil; 
RCVP - Rituximab, cyclophosphamide, vincristine and prednisolone; RCHOP - Rituximab, 
cyclophosphamide, vincristine, doxorubicin and prednisolone; NR – Not reached. 
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Table 3 - Factors affecting overall survival – univariate and multivariate analysis 
 
Factor Median survival 
(months) 
Univariate 
HR (95%CI); p-values 
Multivariate 
HR (95%CI); p-values 
Noise in model: 0.179 
Harrell’s C coef: 0.75 
Age (years) (<67 vs >67) 62 vs 29 1.64 (1.40-1.92); <0.001  1.55 (1.37-1.76); <0.001 
Paraprotein >10 vs <10 48 vs 50 1.27 (1.04-1.54); 0.019 1.22 (0.95-1.56); 0.125 
dFlc (mg/l) (<180 vs >180) 48 vs 19 1.51 (1.07-2.15); 0.021  
NHL type    
MGUS 54 Ref  
WM/LPL 38 1.43 (0.67-3.06); 1.000  
Other NHL 50 1.35 (0.62-2.94); 1.000  
PC 23 1.54 (0.94-2.54); 0.131  
Cardiac vs Non Cardiac 21 vs 62 2.34 (1.65-3.30); <0.001 2.41 (1.07-5.45); 0.034 
Mayo stage   Not included 
     Mayo stage 1  73 Ref  
     Mayo stage 2 24 2.63 (2.14-3.24); <0.001  
     Mayo stage 3 10 4.46 (3.11-6.39); <0.001  
Nt-proBNP(ng/l) (>332 vs <332) 19 vs 73 3.15 (2.66-3.72); <0.001 Not included 
cTnT >0.035 µg/L or cTnI>0.1µg/L 10 vs 57 2.79 (1.96-3.97); <0.001  
Soft tissue vs no Soft tissue 44 vs 55 0.77 (0.49-1.20); 0.244 1.18 (0.53-2.63); 0.690 
PNS vs no PNS 23 vs 50 1.54 (1.21-1.95);  <0.001 1.82 (1.56-2.11); <0.001 
ANS vs no ANS 15 vs 51 2.27 (1.53-3.37); <0.001 1.72 (0.81-3.64); 0.158 
GI vs no GI involvement 24 vs 49 1.19 (0.78-1.84); 0.420 1.43 (0.82-2.47); 0.204 
Renal vs non Renal 43 vs 55 1.26 (0.91-1.75); 0.171 1.26 (0.90-1.75); 0.176 
Liver vs non Liver  21 vs 51 1.36 (1.22-1.52); <0.001 1.57 (0.98-2.51); 0.059 
Albumin (>30g/l vs <30g/l) 50 vs 29 0.64 (0.46-0.89); 0.008 0.56 (0.31-1.02); 0.057 
Organ involvement    
1 69 Ref  
2 48 1.34 (0.79-2.29); 0.563  
>3 19 2.42 (1.73-3.37); <0.001  
Haematological response vs no 
response 
69 vs 28 0.58 (0.38-0.88); 0.012 0.56 (0.33-0.94); 0.028 
Type of haematological response 
NR 28 Ref  
PR 64 0.64 (0.40-1.04); 0.073  
CR/VGPR Not reached 0.36 (0.21-0.61); <0.001  
    
dFLC - difference between involved (amyloidogenic) and uninvolved free light chain; NHL – 
Non-Hodgkins lymphoma; MGUS – Monoclonal gammonpathy of uncertain significance; 
WM/LPL – Waldenstrom’s macroglobinemia / Lymphaplasmacytic lymphoma; PC – Plasma 
cell myeloma; NT-proBNP - N-terminal pro–natriuretic peptide type B; PNS – peripheral 
nervous system; ANS - autonomic nervous system; GI - Gastrointestinal system; NR – Non 
responders; PR – Partial response; CR/VGPR – Complete response / Very good partial 
response. 
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